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Abstract: The discovery and characterization of the RNA interference (RNAi) pathway 
has been one of the most important scientific developments of the last 12 years. RNAi is a 
cellular pathway wherein small RNAs control the expression of genes by either degrading 
homologous RNAs or preventing the translation of RNAs with partial homology. It has 
impacted basic biology on two major fronts. The first is the discovery of microRNAs 
(miRNAs), which regulate almost every cellular process and are required for some viral 
infections, including hepatitis C virus (HCV). The second front is the use of small 
interfering RNAs (siRNAs) as the first robust tool for mammalian cellular genetics. This 
has led to the identification of hundreds of cellular genes that are important for HCV 
infection. There is now a major push to adapt RNAi technology to the clinic. In this 
review, we explore the impact of RNAi in understanding HCV biology, the progress in 
design of RNAi-based therapeutics for HCV, and remaining obstacles. 
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1. A brief history of RNA therapeutics  
In the last 30 years, numerous novel roles for RNA in the regulation of gene expression have been 
discovered in addition to its traditional function as a conveyor of message from DNA to protein. Many 
of these RNA functions have been and will continue to be probed for therapeutic applications. The 
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earliest therapeutic nucleic acids explored were antisense oligonucleotides, typically short   
(13-25  nucleotides (nts)) single-stranded DNA or RNA molecules. Hybridization of an antisense 
molecule with its target RNA results in either degradation by RNase H or steric hindrance of the 
mRNA splicing or translational machinery  [reviewed in 1]. In 1998, the United States Food and Drug 
Administration approved the first antisense DNA drug, fomivirsen by Isis Pharmaceuticals, to treat 
cytomegalovirus retinitis in immuno-compromised patients   [2], thus demonstrating that clinical 
application of therapeutic nucleic acids is an achievable goal.  
Ribozymes and aptamers are RNA molecules identified in the 1980’s that were also tested for 
therapeutic potential. Hammerhead ribozymes, a class of catalytic RNAs (~40 nts), are of particular 
interest because of their ability to recognize and cleave at specific RNA sequences  [3,4]. Aptamers are 
highly structured RNAs (25-40 nts) with a high affinity for their protein ligand making them useful as 
possible drug inhibitors. For example, the transactivation response (TAR) aptamer encoded by   
HIV-1 binds the viral transactivator of transcription protein (Tat), and when over-expressed in vitro, 
TAR renders cells resistant to HIV-1 replication  [5].  
The newest and most promising addition to the field of RNA therapeutics arose from the discovery 
of the RNA interference (RNAi) pathway in 1998 by eventual Nobel Prize recipients Fire and 
Mello   [6]. In C. elegans, Fire et al. noted injection of long, double stranded (ds) RNAs   
(~300-1000 nts) complementary to a specified mRNA was accompanied by efficient elimination of the 
targeted transcript. This phenotype could not be reproduced in mammalian cells until Elbashir et al. 
provided a major breakthrough   [7]. They showed that target mRNAs could be silenced by the 
transfection of cells with chemically synthesized siRNAs, which were designed to mimic the native 
siRNAs produced by RNAi in other systems  [7]. It was subsequently shown that short hairpin RNAs 
(shRNAs), which mimic endogenous pre-miRNAs, could be expressed in cells and also yield effective 
target RNA silencing  [8]. These studies have ushered in a new era of using siRNAs and shRNAs for 
mammalian genetics and therapeutic approaches. While RNAi-based therapeutics have not yet realized 
their considerable potential, much work is being done to advance these approaches into the clinic. 
2. The RNAi pathway 
RNAi is a conserved mechanism of post-transcriptional gene silencing (PTGS) identified in 
multiple organisms, from worms to plants to mammals. Much of the mechanism and key components 
of the RNAi pathway are now appreciated (Figure 1). In the cytoplasm, Dicer, a RNase III type 
enzyme, cleaves long dsRNAs into ~21-25 nucleotide (nt) siRNAs, with 5’ phosphate groups and two 
nt 3’ overhangs  [9,10]. The strand complementary to the target mRNA is called the guide strand while 
the other is called the passenger strand. Clues as to how Dicer recognizes its dsRNA substrate and how 
cleavage sites are chosen lie within its structure   [11,12]. Dicer proteins usually contain a 
helicase/ATPase domain, two RNaseIII-like domains, a PAZ domain, and a dsRNA binding domain. 
The size of siRNAs produced are predicted by the distance between the PAZ and the RNaseIII 
domains, and the 3’ overhangs are a common feature produced by RNaseIII activity  [11]. Several 
positively charged residues connecting these domains are thought to facilitate binding of RNA  [11].  Viruses 2010, 2                  
 
 
1649
Figure 1. Illustration of the endogenous RNAi pathway and therapeutic mimics. 
Genome-encoded primary microRNAs (pri-miRNAs) are processed by Drosha into pre-
miRNAs that are then exported from the nucleus. In the cytosol, Dicer cleaves pre-
miRNAs into miRNAs and a single-stranded guide RNA is incorporated into RISC. 
Depending on sequence homology between the guide strand and the target, RISC either 
cleaves the mRNA or causes translational repression. The RNAi pathway can be activated 
by synthetic siRNAs or shRNAs to therapeutically treat metabolic disorders, cancers, or 
viral infections. shRNAs delivered by viral vectors mimic pre-miRNAs while siRNAs 
mimic the native miRNA duplexes and are incorporated into RISC. shRNAs must be 
exported from the nucleus and siRNAs delivered using liposome-based technologies must 
escape from endosomal compartments before being processed. Accessory proteins 
involved are DiGeorge syndrome critical region 8 (DGCR8), argonaute 2 (ago2), and HIV-
transactivating response RNA-binding protein (TRBP). 
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Dicer then delivers the siRNA to the RNA-induced silencing complex (RISC), in part consisting of 
Dicer, argonaute proteins, and HIV-transactivating response RNA-binding protein (TRBP)   [13]. 
Argonaute 2 (Ago2) is the catalytic endonuclease at the heart of human RISC that binds the siRNA 
duplex, cleaves and removes the passenger strand, and thus leaves behind an intact single-stranded 
guide  [14,15]. The strand with least complementarity at the 5’ end tends to serve as the guide  [16]. 
Furthermore, TRBP binds to the more thermodynamically stable end of the siRNA and orients it with 
Ago2 in a way that helps identify the guide strand  [17]. The degree of complementarity between the 
guide and target mRNA determines whether the mRNA is degraded (exact match) or translationally 
repressed due to steric hindrance (partial homology)  [18]. In the case of exact homology, the RNase H 
domain of Ago2 is responsible for target mRNA cleavage  [14]. 
Endogenous microRNAs (miRNAs) are the natural substrates for Dicer in mammals  [reviewed in 
18]. In the nucleus, RNA polymerase II (Pol II) transcribes genome-encoded primary miRNAs (pri-
miRNAs) that can contain multiple hairpins  [19]. A complex consisting of the RNase III enzyme 
Drosha and dsRNA binding protein DGCR8 cleaves the pri-mRNAs into 60-80 nt hairpins called pre-
miRNAs  [20]. Pre-miRNA hairpins are exported into the cytoplasm where they are recognized by 
Dicer and cleaved to generate the final miRNA duplex with characteristic two nt 3’ overhangs  [20]. 
Novel Dicer-independent mechanisms for miRNA processing may also exist since it was reported that 
miR-451 cleavage relied only on Ago2 catalytic activity in zebrafish  [21]. The majority of miRNA-
derived guide strands have only partial target homology and are directed by RISC to the   
3’ untranslated region (UTR) of mature mRNAs resulting in translational repression  [22]. The “seed” 
region of the miRNA (nts 2-8 from 5’ end of the guide strand) is critical for recognition of target 
3’UTRs   [23]. More recently, it has been shown that central nucleotides can also guide substrate 
selection in some cases  [24]. RNAi is now recognized as a critical regulator of virtually every cellular 
process.  
RNAi has become a preferred method to perform highly specific genetic manipulations for 
functional studies in cell culture. RNAi studies have also greatly expanded the repertoire of possible 
drug targets to treat metabolic and genetic disorders, cancer, or viral infections. The underlying 
principle for RNAi-based therapy is to trigger PTGS using mimics of Dicer substrates (Figure 1): 
either chemically synthesized siRNAs or virally expressed shRNAs. Synthetic siRNAs can be 
delivered to Dicer in the cytosol by a variety of delivery approaches. shRNAs encoded in viral delivery 
vectors must be exported and processed by the endogenous miRNA pathway. 
A study by Song et al. demonstrated the first in vivo siRNA application for disease therapy  [25]. 
They showed that systemic delivery of siRNA duplexes targeting Fas, a mediator of hepatitis and 
fibrosis, resulted in hepatocyte-uptake and protected the treated mice from liver injury in a fulminant 
hepatitis mouse model. More in vivo studies for other diseases soon followed supporting the efficacy 
of siRNA-based therapies   [reviewed in 26, 27]. An array of antiviral RNAi therapies have been 
corroborated in animal models, for example, influenza  [28, 29], respiratory syncytial virus (RSV)  [30, 
31], parainfluenza virus  [30], coxsackievirus B  [32], SARS-associated coronavirus  [33], West Nile 
virus  [34], and herpes simplex virus (HSV-2) using a topical application [35]. Viruses 2010, 2                  
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3. RNAi and HCV 
RNAi is considered an endogenous antiviral mechanism in plants and insects, but it is unlikely to be 
a robust antiviral pathway in mammalian somatic cells  [36]. However, there is some evidence for 
limited antiviral activity of RNAi in mammalian cells. Minor processing of HCV RNAs, in addition to 
those of other viruses, into small RNAs during infection has been reported [37]. Interestingly, 
mammalian viruses that replicate in mosquito vectors, in which RNAi is a primary antiviral pathway, 
had extremely low levels of small RNAs identified in this study. This suggests that viruses that 
successfully infect insects may have evolved counter-strategies to RNAi. On the other hand, viruses 
that do not replicate in insect vectors, such as HCV, had higher levels of short viral RNAs, suggesting 
an absence of evolutionary pressure in mammals to express RNAi antagonists.  
Contrary to the idea that RNAi is a mammalian antiviral mechanism, HCV in fact utilizes RNAi to 
support its infection. HCV replication and infectious virus production were inhibited when 
components of the RNAi pathway, including Dicer, were silenced by siRNAs  [38]. This is likely 
related to a downstream processing effect: the loss of cellular miRNA-122 (miR-122). miR-122 is the 
most abundant miRNA in the liver  [39] and studies suggest it plays a role in fatty acid and cholesterol 
metabolism   [40]. During HCV infection, miR-122 binds to the 5’UTR of the HCV genome and 
regulates both HCV translation and replication by unknown mechanisms  [41-44]. It has been shown 
that genotype 1b HCV replicon replication can be inhibited by sequestering miR-122 [41], and 
infectious J6/JFH-1 replication and virus production can be inhibited by anti-miR-122 RNAs  [38]. A 
much more detailed description of HCV therapeutic approaches targeting miR-122 is described in this 
special issue of Viruses by Catherine Jopling  [45]. Many other viruses, particularly the herpesviruses, 
co-opt the RNAi pathway by expressing viral miRNAs that modulate either cellular or viral gene 
expression  [reviewed in 46].  
Consistent with the lack of an HCV RNAi antagonist, many groups have shown that HCV 
replication is exquisitely sensitive to either chemically synthesized siRNAs or shRNA expression 
targeting HCV RNA. It was reported that siRNAs directly targeting HCV replicon RNAs, specifically 
at the 5’ untranslated region (UTR), core, NS3, NS4B, or NS5A, were effective at reducing viral 
replication and suggests siRNAs can be designed against most regions of the HCV genome  [47-52]. 
The in vitro efficacy of siRNAs against fully infectious HCV has also been shown  [38]. While the 
majority of HCV-siRNAs are complementary to the (+) strand, a reduction in both strands of the viral 
dsRNA replication intermediate has been observed  [53]. It is plausible that targeting the (+) strand 
template indirectly leads to a decrease in synthesis of (-) strands. Although HCV mouse models are 
very limited, some groups have reported RNAi of HCV transgene expression in mice. One in vivo 
mouse study reported shRNAs specific to the HCV 5’UTR were effective at diminishing HCV internal 
ribosome entry site (IRES)-driven luciferase expression  [54]. Another study using a similar method in 
mice reported silencing of a NS5B-luciferase transgene by NS5B-specific siRNAs  [55].  
Because dsRNAs can activate the interferon (IFN) pathway, it was necessary to address whether 
HCV-specific siRNAs could trigger IFN production. Kapadia et al. demonstrated that inhibition of 
viral replication by HCV RNAi in vitro was not associated with an upregulation of IFN-stimulated 
genes   [47]. In fact, HCV siRNAs were better at reducing HCV RNA levels than high doses of   
IFN-α  [47]. An analysis of combined RNAi and IFN treatment of HCV replicons in cell culture using Viruses 2010, 2                  
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lentivirus-delivered shRNAs has been performed. Results indicated that IFN-α did not interfere with 
gene silencing, and inhibition of HCV replication by HCV-specific shRNAs was enhanced by addition 
of IFN-α  [56]. This underscores the possibility of combination therapies of siRNAs and IFN against 
HCV.  
In addition to directly targeting the virus, one important use of RNAi in the HCV therapeutic arena 
that is likely to have success is the identification of novel drug targets by RNAi. In general, this 
approach uses siRNAs or shRNAs targeting cellular genes to identify host cofactors of HCV infection. 
Small molecule inhibitors can then be developed against the identified drug targets. Although host 
genes have traditionally been overlooked as antiviral targets, there is growing interest in the potential 
of host targets to minimize viral resistance and possibly for use as broad-spectrum antivirals. RNAi 
has been used on a small scale to verify that cofactors, such as CD81, PTB, La antigen, and VAP-A 
are important for HCV replication  [57,58]. Many groups have recently published medium-to-high-
throughput RNAi screens that identified hundreds of host factors utilized by HCV   [38,59-64]. 
Identification of cellular proteins with enzymatic functions is ideal for development of novel, small 
molecule inhibitors and/or therapeutic siRNAs. Two such candidates are ubiquitin specific peptidase 
18 (USP18) and phosphatidylinositol 4-kinase III alpha (PI4K-IIIα). siRNAs targeting USP18 have 
been shown to potentiate the ability of IFN-α to inhibit HCV replication and virus production  [65]. 
PI4K-IIIα siRNAs dramatically reduce HCV replication suggesting this is a critical viral replication 
cofactor  [61-64,66,67]. The identification and characterization of host cofactors utilized during HCV 
infection using RNAi technology is a significant advancement towards discovery of much needed new, 
therapeutic targets. 
4. Advantages & pitfalls of RNAi therapeutics  
Since HCV is a major public health burden and the current HCV therapy of IFN and ribavirin is 
successful in only half of treated patients   [68], there are many alternative therapeutics under 
development. Most of these are traditional small molecule approaches inhibiting the function of viral 
proteins. RNAi-based antiviral strategies have a number of distinct advantages and disadvantages as 
compared with these therapies, which are discussed below. One of the primary advantages is that 
siRNAs are easy to design and synthesize, unlike small molecule inhibitors. Several guides and 
algorithms exist to aid in the choice of siRNA   [69]. siRNAs must be experimentally tested for 
efficacy, but this is relatively trivial and typically amenable to high-throughput analysis. They also 
have a distinct target (RNA for siRNAs, versus protein for small molecule inhibitors), which yields 
promise for inclusion in multiple drug cocktails with distinct targets to limit viral escape. However, 
significant challenges remain with respect to RNAi therapy of HCV infection. 
The first obstacle is the relative ease of viral resistance to a siRNA drug. HCV has a high mutation 
rate due to its error prone viral RNA polymerase, which leads to the emergence of drug-resistant 
viruses. In one study, siRNA-resistant HCV replicons emerged after four weeks of HCV-siRNA 
therapy with specific mutations in the target sequence  [70]. In order to minimize the risk of drug 
resistance, multiple viral and/or cellular targets must be considered, as is the case with highly active 
antiretroviral therapy (HAART) for HIV. Delivery of multiple HCV siRNAs in parallel can be 
effective at limiting escape mutants  [53,71]. Alternatively, siRNAs could be also combined with IFN Viruses 2010, 2                  
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treatment or viral protease and polymerase inhibitors. Another approach is to identify highly conserved 
regions of the HCV genome that are susceptible to siRNAs. These sequences should be less likely to 
mutate and provide resistance. 
Another problem is the poor stability of siRNAs in serum which last only minutes due to the high 
concentration of nucleases present in blood   [72]. However, naked siRNAs can be masked with 
chemical modifications for stability while maintaining sequence specificity   [reviewed in 73]. A   
2’-O-methyl addition is the most commonly used modification. The use of a phosphorothioate 
backbone linkage at the 3’ end or a 2’-fluoro sugar modification also offers protection against nuclease 
activity  [74,75]. Furthermore, incorporation of fluoro-β-D-arabinonucleic acid or arabinonucleic acid 
can increase serum stability and potency  [76,77].  
siRNAs may deviate from their intended target and alter the expression from unintended mRNAs, 
which is termed an “off-target effect”. Off-target activity can occur when siRNAs target RISC to the 
3’UTR of an unintended mRNA. This activity is mapped to the “seed” region described for 
miRNAs  [78]. For miRNAs, translational repression occurs when there is exact pairing between the 
seed region (nts 2-8 of the guide strand) and its target 3’UTR, although a partial seed match can also 
trigger silencing given that there is sufficient base-pairing in other regions of the miRNA. This 
flexibility makes it difficult to predict potential off-target activity. For synthetic RNAs, RISC can 
integrate siRNAs into the miRNA pathway to produce translational repression of unintended mRNAs 
containing seed region homology. However, chemical modifications at nucleotide 2 of the seed region 
greatly reduce off-target effects. These include 2’-O-methyl, 2’-fluoro, 2’deoxy, or locked nucleic 
acids (LNAs)  [79]. Additionally, a pool of siRNAs could be used wherein the concentration of an 
individual siRNA is reduced, thus minimizing off-target mRNA repression while enhancing 
specificity. 
Unintended activation of the innate immune response is another complication. Some siRNAs have 
been shown to trigger innate immunity leading to cytokine and interferon production  [80-82]. dsRNAs 
>30 nts activate protein kinase PKR and 2’,5’-oligoadenylate synthetase   [83], but shorter siRNA 
duplexes minimize this activation. siRNAs can also be recognized by the mammalian toll-like 
receptors (TLRs) 3, 7, and 8  [81,84]. TLR3 is a dsRNA sensor, while TLR7 and 8 recognize ssRNA 
and dsRNA motifs. siRNAs targeting vascular endothelial growth factor (VEGF) or its receptor are 
being clinically tested for treatment of wet age-related macular degeneration (AMD). Interestingly, it 
was discovered that siRNAs from two different clinical trials interacted with and activated TLR3, 
thereby indirectly downregulating VEGF  [85]. Thus, the siRNA activity is not sequence-specific and 
is unrelated to the RNAi mechanism. Some siRNAs can bind to TLR7 in a sequence-specific 
manner  [81], but this can be remedied in some cases by adding a 2’-O-methyl modification  [86]. 
Lastly, guanosine and uracil rich regions should be avoided in siRNA design as these may contribute 
to siRNA recognition by TLR7 and TLR8  [87,88].  
An undesired off-target effect unique to viral delivery of shRNAs is the saturation of the RNAi 
machinery. Over-expression of shRNAs was found to saturate nuclear exportin 5, thereby inhibiting 
nuclear export and activity of cellular miRNAs  [89]. Adeno-associated virus 8 (AAV8) is an attractive 
delivery vehicle for HCV therapies due to its improved liver transduction efficiency over other AAV 
vectors  [90]. In a study by Grimm et al., long-term over-expression of shRNAs from an AAV8 vector, 
delivered intravenously in mice, resulted in liver injury that was often fatal   [91]. Again, this Viruses 2010, 2                  
 
 
1654
phenotype was pinpointed to competition between the shRNA and host miRNAs for limiting cellular 
factors. In theory, toxicity can be controlled by lowering the shRNA dosage, either by decreasing the 
amount of virus or the strength of shRNA promoter. Despite the disadvantages mentioned, several 
RNAi-based therapies have successfully made it to clinical trials. As with any potential therapeutic, 
issues of unintended consequences, such as toxicity, should be evaluated in standard pharmacokinetic 
and phase I safety studies. 
5. siRNA drugs in clinical trials 
siRNA drugs are promising treatments for many diseases  [reviewed in 92-94]. The first generation 
of therapies was designed to treat wet AMD, the major cause of blindness in the United States in 
patients over the age of 55. The first highly anticipated siRNA therapy to advance to phase III clinical 
trials was intravitreal injection of bevasiranib (Opko Health), designed to target VEGF for treatment of 
wet AMD. While it showed promising activity in combination with an anti-VEGF antibody, 
ranibizumab (Genentech), the trial was predicted not to reach its therapeutic potential and was 
terminated in March 2009  [95]. In a collaboration between Merck-siRNA Therapeutics and Allergan, 
the AMD drug called AGN211745 (formerly sirna-027), which is a chemically modified siRNA 
targeting VEGF receptor 1, also held promise but did not pass phase II trials in 2009  [95]. Despite 
these two setbacks, PF-4523655 (formerly RTP801i-14) from Quark Pharmaceuticals and Pfizer is a 
siRNA currently in phase II trials for use in AMD and also diabetic macular degeneration. 
Using a more advanced approach, CALAA-01 (Calando Pharmaceuticals) is a RNAi therapeutic 
candidate for treatment of solid tumors and consists of transferrin-coated cyclodextrin nanoparticles 
containing siRNAs that target the M2 subunit of ribonucleotide reductase (RRM2), a cancer 
target  [96]. A recent report shows that systemic administration of CALAA-01, currently in phase 1 
trials, specifically inhibits the intended mRNA transcript in humans  [96], unlike the off-target effects 
reported for other clinical RNAi therapies  [85]. This is the first evidence of a RNAi therapeutic in 
humans that indeed works by a RNAi mechanism. Dependent on upregulated transferrin receptors in 
cancer cells, this is also the first clinical siRNA therapy to utilize receptor-mediated delivery. Silence 
Therapeutics AG has developed a unique siRNA-lipoplex formulation to target protein kinase N3 
(PKN3), an effector of the PI3-kinase pathway  [97]. This drug (Atu027) is being explored in phase I 
trials for anti-angiogenesis therapy of advanced solid cancers. siRNA-mediated treatment to boost the 
immune response against metastatic melanoma is also in phase I (Duke University). For this study, 
patients are injected with autologous dendritic cells transfected with melanoma tumor antigen 
expression constructs and siRNAs targeting the immunoproteosome   [98], presumably to enhance 
melanoma antigen presentation. 
The first antiviral siRNA drug approved for clinical trials targets respiratory syncytial virus (RSV). 
RSV causes respiratory tract infections that are most severe in children. ALN-RSV01 (Alnylam 
Pharmacuetical) targets the RSV nucleocapsid and inhibits viral replication in the lung  [99]. Findings 
from phase II trials, involving healthy adults experimentally inoculated with RSV, have now been 
published  [99]. Both prevention and treatment modalities were incorporated into the trial design. In 
either modality, viral loads were diminished in patients treated with ALN-RSV01 as compared to 
placebo. However, the most significant antiviral effect was observed when it was administered Viruses 2010, 2                  
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prophylactically. A phase II trial testing efficacy of ALN-RSV01 in naturally infected lung transplant 
patients has been completed and now a phase IIb has begun  [98]. Benitec, in collaboration with the 
City of Hope National Medical Center in California, published its phase I clinical trial for RNAi 
therapy of HIV-1 in June 2010  [100]. Autologous CD34+ cells from HIV patients with AIDS-related 
lymphoma were modified with a triple combination vector (rHIV7-shI-TAR-CCR5RZ) consisting of a 
shRNA targeting a tat/rev exon, a TAR RNA decoy, and a CCR5 targeting hammerhead ribozyme. 
This combination afforded long term suppression of HIV replication in a prior in vitro study  [101], 
and the clinical results show it is feasible, well tolerated in patients, and has sustained expression up to 
24 months  [100].  
Lastly, the safety of a therapeutic for HCV that targets miR-122 is being analyzed in phase I clinical 
trials. SPC3649 (Santaris Pharma) is a LNA-modified phosphorothioate oligonucleotide that was 
published to effectively silence miR-122 in African green monkeys  [102] and produce prolonged 
suppression of viremia without HCV resistance in chronically infected chimpanzees   [103] with 
tolerated reduction in cholesterol levels. Phase I clinical trials of SPC3649 began this year, with a 
competing anti-miR-122 antiviral developed by GlaxoSmithKline and Regulus Therapeutics scheduled 
for phase I trial in 2011  [104]. These clinical studies pave the way to designing effective RNAi 
strategies in patients. 
6. The final frontier for RNAi therapeutics for HCV: effective siRNA delivery to the liver 
The major challenge now is to progress from HCV in vitro “proof of concept” studies to in vivo 
therapeutic approaches using siRNAs or shRNAs. This has been especially challenging for HCV due 
to limited animal models. The greatest breakthrough for HCV RNA therapeutics thus far has not been 
siRNAs or shRNAs, but the anti-miR-122 drug SPC3649, which to date is the only successful 
treatment in a HCV animal model supportive of these approaches. By far the biggest hurdle in HCV 
siRNA therapy is the efficient delivery of siRNAs to the cytosol of infected hepatocytes. This entails 
maximizing both the uptake of siRNA by the liver and the escape of siRNAs from the endocytic 
compartments into the cytosol. The liver is an attractive organ for uptake of nucleic acids following 
systemic delivery as evidenced by several reports showing naked siRNAs are readily taken up by the 
liver in mice using hydrodynamic tail vein injection  [25,55,105,106]. This delivery approach involves 
rapid, large volume injection and is not amenable to use in humans. The amounts of siRNAs required 
for a therapeutic effect against hepatitis B virus (HBV) using intravenous injection in an animal model 
were an order of magnitude above conceivable therapeutic doses in people  [106]. Nevertheless, this 
method was important in first demonstrating siRNA efficacy in hepatocytes in vivo. There are multiple 
approaches being taken to improve uptake and delivery to the liver, which are outlined below. 
One approach to improve specific organ delivery is conjugation of siRNAs to biologically relevant 
molecules. The strategy behind lipophilic modifications to siRNAs depends on binding to lipoproteins 
and internalization by low-density or high-density lipoprotein (LDL or HDL) receptors, which are 
highly expressed in the liver. Intravenous injection of cholesterol-conjugated siRNAs for 
apolipoprotein B (apoB) was effective at silencing transcripts in the liver and jejunum of mice, 
resulting in lowered cholesterol levels  [107]. siRNAs conjugated to bile-salt derivatives or long chain 
fatty acids were also found to trigger RNAi in hepatocytes in vivo  [108]. Vitamin E (α-tocopherol) is Viruses 2010, 2                  
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incorporated into lipoproteins after consumption, including LDLs and HDLs  [109]. With this in mind, 
Nishina  et al. showed that α-tocopherol-conjugated siRNAs (Toc-siRNAs) specific to apoB were 
effectively delivered and processed by Dicer in livers of mice without stimulating IFN 
production  [110].  
The negatively charged plasma membrane, circulating nucleases present in serum, and rapid 
clearance by the renal system impede uptake of siRNAs. One approach to overcome issues of 
membrane charge and nucleases is the incorporation of siRNAs into multilayered polyelectrolyte films 
(MPFs), which consist of alternating layers of polycations and polyanions wherein siRNAs are semi-
protected from spontaneous release or diffusion until cell uptake  [111]. Using this method, Dimitrova 
et al. showed effective and sustainable inhibition of HCV replication in cell culture using HCV 
siRNAs complexed within MPFs   [111]. Another approach is the use of stable nucleic acid lipid 
particles (SNALPS) which contain siRNAs within a combination of cationic and fusogenic lipids 
coated with polyethelene glycol (PEG) [106]. SNALPS have been successfully used to deliver anti-
HBV siRNAs to inhibit HBV replication in mouse hepatocytes and to deliver anti-apoB siRNAs in 
mice and monkeys  [106,112]. Other types of cationic lipid-based vehicles have been developed based 
on a library of cationic lipid-like molecules, called lipidoids, that were generated by adding primary or 
secondary amines to alkyl-acrylates or alkyl-acrylamides  [113]. The leading compound identified, 
98N12-5(1), when combined with cholesterol and PEG lipid, effectively encapsulated and delivered 
siRNAs to mouse hepatocytes. Although, cationic liposomes have improved hepatic delivery, siRNA 
uptake is often observed in other organs. Also, liposome-siRNA based technologies face the problem 
of escaping the endosome once they are internalized. Endosomal release can be facilitated by 
incorporating fusogenic peptides and ligands or by using pH-sensitive nanocomplexes  [reviewed in 
114]. 
A unique technology called dynamic polyconjugates (DPCs) addresses issues of cell-specific 
targeting and endosomal escape. DPCs consist of the hepatocyte targeting ligand   
N-acetylgalactosamine conjugated to PEG (used as a shielding agent to prevent non-specific 
interactions of the nanoparticle) and to an endosomolytic polymer that is activated only in the acidic 
environment of the endosome. Using a single simple intravenous injection of anti-apoB siRNAs 
carried by DPCs, Rozema et al. reported specific reduction of apoB mRNA in the liver (hepatocytes 
specifically and not Kupffer cells) and not in the jejunum of mice  [115], thus demonstrating the 
effectiveness of utilizing a targeting ligand. 
Viral vectors are another means of triggering RNAi in hepatocytes. shRNAs are cloned into viral 
vectors under control of Pol II or Pol III promoters and typically packaged into lentivirus, adenovirus, 
or AAV particles. Viral encoded and delivered shRNAs have the benefit of long-term expression in 
dividing and non-dividing cells and incorporation of target ligands. To direct viral vectors to specific 
cells, target ligands can be incorporated into the viral particles or liver-specific RNA pol promoters 
used to drive shRNA expression. Viruses that have a natural tropism for certain tissues can be used, as 
in the case of hepatropic AAV8. However, as mentioned earlier, the downside of viral-encoded 
shRNAs is RNAi saturation and toxicity  [91].  Viruses 2010, 2                  
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7. Conclusions and outlook 
The identification of RNAi in mammalian cells is less than a decade old. However, the field has 
dramatically altered our fundamental understanding of gene regulation in almost every setting. It is 
clear that there is an enormous potential for RNAi-based therapies, which is as of yet unrealized. In the 
case of HCV, RNAi therapies will not be the next generation of antivirals to emerge from clinical 
trials. These almost certainly will be more classical protease and polymerase small molecule inhibitors 
that will be used in combination with IFN and ribavirin. Nevertheless, it is clear that additional 
therapeutic strategies involving novel targets will likely be required to treat patients who fail to 
respond to this combination therapy, which is proposed to be ~15-25% of treated patients  [116]. It is 
possible that RNAi therapeutics may be one of the next generations of drugs to help fill this niche. 
The compelling strength of RNAi therapeutic approaches is that once the proper modifications are 
designed to minimize off-target effects, while maximizing effective delivery of siRNAs or shRNAs to 
the hepatic cytosol, they are universally applicable to any liver target. Only the siRNA nucleotide 
sequence needs to change in order to target any hepatotropic virus or liver gene target, e.g. to treat 
diseases with elevated LDL or cholesterol. Thus, if the issues with effective delivery are overcome, it 
will be trivial to apply this technology to many different hepatotropic diseases.  
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